Mather Group LLC. Makes New Investment in Structure Therapeutics Inc. (NASDAQ:GPCR)

Mather Group LLC. purchased a new stake in shares of Structure Therapeutics Inc. (NASDAQ:GPCR) in the second quarter, HoldingsChannel.com reports. The fund purchased 5,000 shares of the company’s stock, valued at approximately $214,000.

Other institutional investors have also modified their holdings of the company. Sectoral Asset Management Inc. purchased a new stake in shares of Structure Therapeutics during the fourth quarter worth about $139,000. ADAR1 Capital Management LLC acquired a new stake in Structure Therapeutics during the fourth quarter worth approximately $163,000. Raymond James & Associates purchased a new stake in Structure Therapeutics in the 4th quarter worth approximately $233,000. New York State Common Retirement Fund acquired a new position in Structure Therapeutics in the 4th quarter valued at $277,000. Finally, Virtu Financial LLC purchased a new position in shares of Structure Therapeutics during the 1st quarter worth $308,000. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Analyst Ratings Changes

Several research firms have commented on GPCR. JMP Securities restated a “market outperform” rating and issued a $91.00 price target on shares of Structure Therapeutics in a report on Friday, May 10th. Cantor Fitzgerald restated an “overweight” rating and issued a $65.00 target price on shares of Structure Therapeutics in a report on Monday, July 1st. BMO Capital Markets increased their price target on shares of Structure Therapeutics from $83.00 to $100.00 and gave the stock an “outperform” rating in a research note on Friday, June 7th. Finally, JPMorgan Chase & Co. started coverage on shares of Structure Therapeutics in a report on Tuesday, May 21st. They issued an “overweight” rating and a $65.00 price target on the stock. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $85.25.

Structure Therapeutics Stock Down 1.7 %

NASDAQ GPCR traded down $0.58 on Wednesday, hitting $34.54. The stock had a trading volume of 128,298 shares, compared to its average volume of 818,185. The company’s 50-day moving average is $42.17 and its two-hundred day moving average is $40.90. Structure Therapeutics Inc. has a one year low of $25.57 and a one year high of $75.02. The stock has a market cap of $1.61 billion, a price-to-earnings ratio of -45.61 and a beta of -3.52.

Structure Therapeutics (NASDAQ:GPCR) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.02. On average, sell-side analysts anticipate that Structure Therapeutics Inc. will post -0.94 earnings per share for the current year.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.